GlaxoSmithKline PLC - West London-based pharmaceutical firm - ViiV Healthcare, the HIV joint venture of GSK, Pfizer Inc and Shionogi & Co Ltd, secures approval from US Food & Drug Administration for Apretude, a long-acting injectable option for HIV prevention.
Says trials show cabotegravir, marketed as Apretude, demonstrates superior efficacy to a daily oral PrEP option in reducing the risk of HIV acquisition.
Deborah Waterhouse, chief executive of ViiV Healthcare, says: "People who are vulnerable to acquiring HIV, especially those in Black and Latinx communities who are disproportionately impacted in the US, may want options beyond daily oral pills. That's why ViiV Healthcare is proud that Apretude was studied in one of the most diverse and comprehensive HIV prevention trial programs to date, which also included some of the largest numbers of transgender women and Black men who have sex with men ever enrolled in an HIV prevention trial.
"With Apretude, people can reduce the risk of acquiring HIV with as few as six injections a year. Today's approval is the latest example of ViiV Healthcare's commitment to developing long-acting medicines that offer consumers a different choice."
Current stock price: 1,585.80 pence
Year-to-date change: up 18%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
